April 3 (Reuters) - ARCA Biopharma Inc :
* ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT
* ARCA BIOPHARMA AND ORUKA THERAPEUTICS ANNOUNCE MERGER AGREEMENT
* ARCA BIOPHARMA INC - UNDER TERMS OF MERGER AGREEMENT, PRE-MERGER ARCA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 2.38% OF COMBINED COMPANY
* ARCA BIOPHARMA INC - COMBINED COMPANY PLANS TO OPERATE UNDER NAME ORUKA THERAPEUTICS, INC. AND TRADE ON NASDAQ UNDER TICKER SYMBOL "ORKA"
* ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027
* ARCA BIOPHARMA INC - PRE-MERGER ORUKA STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 97.62% OF COMBINED COMPANY
* ARCA BIOPHARMA INC - ARCA IS EXPECTED TO CONTRIBUTE $5 MILLION TO COMBINED ENTITY
* ARCA BIOPHARMA INC: PRE-CLOSING PRIVATE FINANCING OF APPROXIMATELY $275 MILLION ANTICIPATED TO FUND OPERATIONS THROUGH 2027
* ARCA BIOPHARMA INC - EXPECTS TO PAY A DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS OF APPROXIMATELY $20 MILLION IMMEDIATELY PRIOR TO CLOSE OF MERGER
* ARCA BIOPHARMA INC - COMBINED COMPANY WILL BE NAMED ORUKA THERAPEUTICS, INC. AND LED BY LAWRENCE KLEIN, ORUKA'S CURRENT CHIEF EXECUTIVE OFFICER
* ARCA BIOPHARMA INC: EXPECTS TO DECLARE A CASH DIVIDEND TO PRE-MERGER ARCA STOCKHOLDERS EQUAL TO AMOUNT BY WHICH ARCA'S NET CASH EXCEEDS $5 MILLION.
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。